Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Go back to Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform| (NASDAQ: NTLA) | Delayed: 12.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.74 | 52 Week High | $30.40 | |||
| Open | $12.83 | 52 Week Low | $11.86 | |||
| Day High | $12.89 | P/E | N/A | |||
| Day Low | $12.43 | EPS | $0.00 | |||
| Volume | 4,129,194 | |||||
